Patents by Inventor Joerg Thomas Regula

Joerg Thomas Regula has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10538585
    Abstract: Herein are reported anti-ANG2 antibodies. A specific anti-ANG2 antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 20, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 21, and (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 23.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: January 21, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Guy Georges, Peter Michael Huelsmann, Hubert Kettenberger, Joerg Moelleken, Michael Molhoj, Joerg Thomas Regula
  • Publication number: 20190382507
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.
    Type: Application
    Filed: July 25, 2019
    Publication date: December 19, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Joerg Thomas Regula, Pablo Umana
  • Publication number: 20190322748
    Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: March 27, 2019
    Publication date: October 24, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: LAURA CODARRI-DEAK, GEORG FERTIG, JENS FISCHER, CHRISTIAN KLEIN, VIKTOR LEVITSKI, VALERIA LIFKE, MARIO PERRO, JOERG THOMAS REGULA, TILMAN SCHLOTHAUER, STEFAN SEEBER, PABLO UMANA, ILDIKO WUENSCHE, ADRIAN ZWICK
  • Patent number: 10392445
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: August 27, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Joerg Thomas Regula, Pablo Umana
  • Patent number: 10287352
    Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: May 14, 2019
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Laura Codarri-Deak, Georg Fertig, Jens Fischer, Christian Klein, Viktor Levitski, Valeria Lifke, Mario Perro, Joerg Thomas Regula, Tilman Schlothauer, Stefan Seeber, Pablo Umana, Ildiko Wuensche, Adrian Zwick
  • Publication number: 20190016827
    Abstract: Herein is reported a method for determining the binding interaction with a multimeric antigen of an antibody of the human IgG1 subclass that has at least two binding sites specifically binding to the antigen comprising the steps of 1) determining the binding affinity of the antibody for the multimeric antigen, and 2) incubating a mixture comprising the antibody and a polypeptide that is derived from lysine-gingipain of porphyromonas gingivalis under conditions and for a time sufficient to cleave the antibody into Fabs and Fc-region, and determining the binding affinity of the Fabs of the antibody for the multimeric, whereby the binding affinity of the antibody to the multimeric antigen to be affinity-driven if the binding affinity determined in both steps are comparable and to be avidity-driven if the binding affinity determined in both steps are different.
    Type: Application
    Filed: June 8, 2018
    Publication date: January 17, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg MOELLEKEN, Michael MOLHOJ, Christian GASSNER, Manuel ENDESFELDER, Joerg-Thomas REGULA
  • Publication number: 20180312573
    Abstract: The present invention relates to antigen binding proteins comprising two Fc parts, methods for their production, pharmaceutical compositions containing said antigen binding proteins, and uses thereof.
    Type: Application
    Filed: April 24, 2018
    Publication date: November 1, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Birgit BOSSENMAIER, Hubert KETTENBERGER, Christian KLEIN, Klaus-Peter KUENKELE, Joerg-Thomas REGULA, Wolfgang SCHAEFER, Manfred SCHWAIGER, Claudio SUSTMANN
  • Patent number: 10106600
    Abstract: The present invention relates to bispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: October 23, 2018
    Assignee: Roche Glycart AG
    Inventors: Ulrich Brinkmann, Rebecca Croasdale, Harald Duerr, Christian Klein, Erhard Kopetzki, Wilma Lau, Joerg Thomas Regula, Juergen Michael Schanzer, Pablo Umana, Katharina Wartha
  • Publication number: 20180282410
    Abstract: The present invention generally relates to bispecific antigen binding molecules for activating T cells, more particularly bispecific antigen binding molecules for activating T cells targeting the Robo 4 receptor. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease. In addition, the invention also relates to antibodies that specifically bind to Robo 4.
    Type: Application
    Filed: September 29, 2016
    Publication date: October 4, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Oliver AST, Marina BACAC, Sabine BAUER, Sabine IMHOF-JUNG, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Samuel MOSER, Christiane NEUMANN, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMA√ĎA, Tina WEINZIERL
  • Publication number: 20180282404
    Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: February 28, 2018
    Publication date: October 4, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
  • Patent number: 10087246
    Abstract: Herein are reported anti-PDGF-B antibodies and their use in ophthalmology.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: October 2, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marc Bedoucha, Sebastian Breuer, Stefan Dengl, Christian Gassner, Guy Georges, Sabine Gruener, Guido Hartmann, Peter Michael Huelsmann, Joerg Moelleken, Olaf Mundigl, Joerg Thomas Regula, Barbara Weiser
  • Publication number: 20180222992
    Abstract: Herein are provided bispecific anti-human A-beta/human transferrin receptor antibodies and methods of using the same.
    Type: Application
    Filed: March 30, 2018
    Publication date: August 9, 2018
    Inventors: Harald Duerr, Sebastian Fenn, Ulrich Goepfert, Sabine Imhof-Jung, Christian Klein, Laurent Lariviere, Michael Molhoj, Joerg Thomas Regula, Petra Rueger, Wolfgang Schaefer
  • Publication number: 20180222980
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: January 24, 2018
    Publication date: August 9, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Oliver AST, Marina BACAC, Sabine IMHOF-JUNG, Christiane JAEGER, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMANA
  • Publication number: 20180222993
    Abstract: Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.
    Type: Application
    Filed: March 30, 2018
    Publication date: August 9, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Harald DUERR, Sebastian FENN, Ulrich GOEPFERT, Sabine IMHOF-JUNG, Christian KLEIN, Laurent LARIVIERE, Michael MOLHOJ, Joerg Thomas REGULA, Petra RUEGER, Wolfgang SCHAEFER
  • Publication number: 20180222981
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: January 24, 2018
    Publication date: August 9, 2018
    Inventors: Oliver AST, Marina BACAC, Sabine IMHOF-JUNG, Christiane JAEGER, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMANA
  • Publication number: 20180164325
    Abstract: The current invention is directed to a method for the determination of the glycosylation pattern of a human immunoglobulin of the subclass IgG1 or IgG4 or of a murine immunoglobulin of the subclass IgG2a or IgG3 comprising the following steps: a) cleaving said immunoglobulin into fragments by enzymatic digestion with the enzyme IdeS, b) separating the fragments of said immunoglobulin obtained by the enzymatic digestion by reversed phase high performance liquid chromatography, c) subjecting the separated fragments of said immunoglobulin obtained in step b) to a mass spectrometric analysis, and d) determining the glycosylation pattern of said immunoglobulin from the mass spectrometric data obtained in step c).
    Type: Application
    Filed: August 1, 2017
    Publication date: June 14, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Hans Koll, Joerg Thomas Regula, Peter Sondermann, Anne Zeck
  • Patent number: 9982036
    Abstract: The present invention relates to antigen binding proteins comprising two Fc parts, methods for their production, pharmaceutical compositions containing said antigen binding proteins, and uses thereof.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: May 29, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, Hubert Kettenberger, Christian Klein, Klaus-Peter Kuenkele, Joerg-Thomas Regula, Wolfgang Schaefer, Manfred Schwaiger, Claudio Sustmann
  • Publication number: 20180079805
    Abstract: The present invention relates to bispecific antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: April 24, 2017
    Publication date: March 22, 2018
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Sabine IMHOF-JUNG, Christian KLEIN, Joerg Thomas REGULA, Wolfgang SCHAEFER, Juergen Michael SCHANZER
  • Patent number: 9914776
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: March 13, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Oliver Ast, Marina Bacac, Sabine Imhof-Jung, Christiane Jaeger, Christian Klein, Stefan Klostermann, Michael Molhoj, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
  • Publication number: 20180037633
    Abstract: The present invention relates to monovalent antigen binding proteins with a CH1-CL domain exchange, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: June 12, 2017
    Publication date: February 8, 2018
    Inventors: Birgit BOSSENMAIER, Hubert KETTENBERGER, Christian KLEIN, Klaus-Peter KUENKELE, Joerg Thomas REGULA, Wolfgang SCHAEFER, Manfred SCHWAIGER, Claudio SUSTMANN